Despite the profitability miss, FY 23/24 guidance unchanged
09/02/24 -"CZM’s Q1 profitability fell short of expectations. Growth was once again led by Microsurgery, while Ophthalmology ended on a flat note. As expected, profitability was under pressure. Nonetheless, FY ..."
Pages
65
Language
English
Published on
09/02/24
You may also be interested by these reports :
05/12/25
In addition to revising our estimates downwards to address near-term challenges, we have also injected a 20% discount into peer-based valuation ...
05/12/25
On the back of promising operating results, which also prompted management to upgrade its guidance, our estimates reset higher. This is commendable, ...
05/12/25
We have incorporated the actual figures for the FY24/25 ending in June 2025. While the recurring EBIT was in line with our forecast (€44.2m vs ...
03/12/25
Despite challenges that have reduced our target price, Demant still presents a significant upside. The company is poised to benefit from: 1) new ...